These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32832636)

  • 1. Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer.
    Zhao Z; Li Y; Liu H; Jain A; Patel PV; Cheng K
    Sci Adv; 2020 Jul; 6(29):eabb0616. PubMed ID: 32832636
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
    Zhao Z; Li Y; Shukla R; Liu H; Jain A; Barve A; Cheng K
    Theranostics; 2019; 9(15):4508-4524. PubMed ID: 31285776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer.
    Luo K; Gao Y; Yin S; Yao Y; Yu H; Wang G; Li J
    Acta Biomater; 2021 Oct; 134():649-663. PubMed ID: 34289420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE.
    Qiao J; Chen Y; Mi Y; Jin H; Wang L; Huang T; Li H; Song Y; Cao J; Wu B; Wang Q; Zou Z
    Biochem Pharmacol; 2020 Oct; 180():114126. PubMed ID: 32603665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery.
    Patel P; Fetse J; Lin CY; Guo Y; Hasan MR; Nakhjiri M; Zhao Z; Jain A; Cheng K
    Acta Biomater; 2022 Dec; 154():374-384. PubMed ID: 36191773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated kinase screening identifies the
    Leonardi M; Perna E; Tronnolone S; Colecchia D; Chiariello M
    Autophagy; 2019 Feb; 15(2):312-326. PubMed ID: 30289335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted delivery of CD44s-siRNA by ScFv overcomes de novo resistance to cetuximab in triple negative breast cancer.
    Fu W; Sun H; Zhao Y; Chen M; Yang L; Yang X; Jin W
    Mol Immunol; 2018 Jul; 99():124-133. PubMed ID: 29777999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
    Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
    Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rad51 Silencing with siRNA Delivered by Porous Silicon-Based Microparticle Enhances the Anti-Cancer Effect of Doxorubicin in Triple-Negative Breast Cancer.
    Wu Z; Zhu L; Mai J; Shen H; Xu R
    J Biomed Nanotechnol; 2021 Dec; 17(12):2351-2363. PubMed ID: 34974858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA.
    Zhang L; Mu C; Zhang T; Yang D; Wang C; Chen Q; Tang L; Fan L; Liu C; Shen J; Li H
    J Nanobiotechnology; 2021 Jan; 19(1):13. PubMed ID: 33413427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budlein A methylacrylate demonstrates potent activity against triple-negative breast cancer by targeting IκBα kinase and exportin-1.
    Wang XZ; Feng Y; Han YF; Bian Y; Liang J; Wen HM; Wu H
    Toxicol Appl Pharmacol; 2020 Dec; 408():115263. PubMed ID: 33022283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronic acid-modified redox-sensitive hybrid nanocomplex loading with siRNA for non-small-cell lung carcinoma therapy.
    Chen D; Zhang P; Li M; Li C; Lu X; Sun Y; Sun K
    Drug Deliv; 2022 Dec; 29(1):574-587. PubMed ID: 35156491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
    Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
    Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells.
    Zhang C; Yuan W; Wu Y; Wan X; Gong Y
    Life Sci; 2021 Feb; 266():118886. PubMed ID: 33310044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
    Parvani JG; Gujrati MD; Mack MA; Schiemann WP; Lu ZR
    Cancer Res; 2015 Jun; 75(11):2316-2325. PubMed ID: 25858145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.